EMVision Prepares to Add Acute Ischemia Detection Endpoint to Brain Scanner Validation Trial; Shares Up 8%

MT Newswires Live

Jul 15

EMVision Medical Devices (ASX:EMV) is advancing preparations to add an acute ischemia detection endpoint to its pivotal validation trial for its point-of-care brain scanning device, with US Food and Drug Administration (FDA) meeting and protocol amendment planned, according to a Wednesday Australian bourse filing.

The trial is a multi-center, prospective, blinded diagnostic performance study designed to support US FDA De Novo clearance for its emu brain scanner product, per the filing. The primary objective of the trial is to demonstrate hemorrhage detection sensitivity and specificity of greater than 80%.

A first responder aeromedical feasibility and usability study for its pre-hospital brain scanning device with Royal Flying Doctor Service was completed during the June quarter, the filing said.

The company's shares rose past 8% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2651363594"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651363594\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651363594?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 11:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651363594","market":"us","top_or_hot":-1,"title":"EMVision Prepares to Add Acute Ischemia Detection Endpoint to Brain Scanner Validation Trial; Shares Up 8%","media":"MT Newswires Live","content":"<html><body><p> EMVision Medical Devices (ASX:EMV) is advancing preparations to add an acute ischemia detection endpoint to its pivotal validation trial for its point-of-care brain scanning device, with US Food and Drug Administration (FDA) meeting and protocol amendment planned, according to a Wednesday Australian bourse filing.</p><p>The trial is a multi-center, prospective, blinded diagnostic performance study designed to support US FDA De Novo clearance for its emu brain scanner product, per the filing. The primary objective of the trial is to demonstrate hemorrhage detection sensitivity and specificity of greater than 80%.</p><p>A first responder aeromedical feasibility and usability study for its pre-hospital brain scanning device with Royal Flying Doctor Service was completed during the June quarter, the filing said.</p><p>The company's shares rose past 8% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EMVision Prepares to Add Acute Ischemia Detection Endpoint to Brain Scanner Validation Trial; Shares Up 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEMVision Prepares to Add Acute Ischemia Detection Endpoint to Brain Scanner Validation Trial; Shares Up 8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-15 11:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> EMVision Medical Devices (ASX:EMV) is advancing preparations to add an acute ischemia detection endpoint to its pivotal validation trial for its point-of-care brain scanning device, with US Food and Drug Administration (FDA) meeting and protocol amendment planned, according to a Wednesday Australian bourse filing.</p><p>The trial is a multi-center, prospective, blinded diagnostic performance study designed to support US FDA De Novo clearance for its emu brain scanner product, per the filing. The primary objective of the trial is to demonstrate hemorrhage detection sensitivity and specificity of greater than 80%.</p><p>A first responder aeromedical feasibility and usability study for its pre-hospital brain scanning device with Royal Flying Doctor Service was completed during the June quarter, the filing said.</p><p>The company's shares rose past 8% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EMV.AU","symbol_name":"EMVISION MEDICAL DEVICES LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651363594","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651363594","pubTimestamp":1784086464,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"EMVision Medical Devices  is advancing preparations to add an acute ischemia detection endpoint to its pivotal validation trial for its point-of-care brain scanning device, with US Food and Drug Administration  meeting and protocol amendment planned, according to a Wednesday Australian bourse filing.The trial is a multi-center, prospective, blinded diagnostic performance study designed to support US FDA De Novo clearance for its emu brain scanner product, per the filing. The primary objective of the trial is to demonstrate hemorrhage detection sensitivity and specificity of greater than 80%.A first responder aeromedical feasibility and usability study for its pre-hospital brain scanning device with Royal Flying Doctor Service was completed during the June quarter, the filing said.The company's shares rose past 8% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EMV.AU":"EMVISION MEDICAL DEVICES LTD","BK7007":"医疗保健设备"},"translate_title":"EMVision准备在脑扫描仪验证试验中加入急性缺血检测终点；股价上涨 8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMV.AU":1},"content_text":"EMVision Medical Devices (ASX:EMV) is advancing preparations to add an acute ischemia detection endpoint to its pivotal validation trial for its point-of-care brain scanning device, with US Food and Drug Administration (FDA) meeting and protocol amendment planned, according to a Wednesday Australian bourse filing.The trial is a multi-center, prospective, blinded diagnostic performance study designed to support US FDA De Novo clearance for its emu brain scanner product, per the filing. The primary objective of the trial is to demonstrate hemorrhage detection sensitivity and specificity of greater than 80%.A first responder aeromedical feasibility and usability study for its pre-hospital brain scanning device with Royal Flying Doctor Service was completed during the June quarter, the filing said.The company's shares rose past 8% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}